Exploring clinical endpoints
Widely used criteria for determining the effectiveness of new oncology drugs1
Multiple clinical endpoints have been designed to measure the anti-tumor activity of targeted TKI therapies in patients with locally advanced or metastatic NSCLC.1
The RECIST guideline has been adopted by researchers, health industry experts and government authorities as the standard approach to assessing clinical outcomes in patients with NSCLC for trials where the primary endpoints are objective response or progression.1
The following sections provide a summary of the RECIST guideline. Please refer to the full guideline as necessary for more information.
NSCLC: non-small-cell lung cancer; RECIST: Response Evaluation Criteria In Solid Tumors; TKI: tyrosine kinase inhibitor.
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45:228–47.